Regulatory Inspections Get Serious - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Regulatory Inspections Get Serious
Siegfried Schmitt of PAREXEL explains how regulatory agencies are getting serious about inspections.

Pharmaceutical Technology
Volume 37, Issue 8, pp. 94


Siegfried Schmitt
Q. Are inspections getting tougher?
A. Many reviews of regulatory inspection activities focus on the top 10 citations/findings, which say a lot about the areas of concern, but little about how these inspections are conducted or whether or not inspections are getting tougher. Several agencies publish their inspection standard operating procedures (SOPs) or how they inspect (1, 2). This gives the industry a good idea how the inspection will be conducted and what areas will be looked at. The industry has studied these documents and learned from inspections over the years. Consequently, one should assume that all is well under control, but is it?

FDA inspections

Feedback from both inspected companies and consulting firms points to a significant change in the focus of FDA inspections of foreign drug establishments and the expected response by the inspectors. This change has caught many companies by surprise. The following examples clarify the observed change:

  • A multinational European manufacturer had been inspected regularly and apart from the occasional observation on form FDA-483 did not have any issues of note. During the most recent inspection by FDA, the same common areas, such as deviation management and the associated corrective and preventive action (CAPA) process were scrutinized. There was no lenience when it came to incomplete or ambiguous records for root cause analysis or delayed completion of CAPA. The argument "but we have always done it this way" only contributed to FDA's issuance of a warning letter.
  • A large Asian company with a good history of compliance received a series of FDA-483 observations to which they responded in the same manner as for previous inspections. However, where it had been sufficient in the past to describe CAPA actions specific to the findings, FDA dismissed their response as not addressing the totality of the findings in a holistic and encompassing way. Where FDA now states that they consider the integrity of the quality system compromised, a review of the entire system is expected. Any response that falls short of this expectation can have serious consequences, such as an import ban.
  • Another company learned that implementation of International Conference on Harmonization (ICH) Q7, Q8, Q9, Q10, and Q11 guidelines is now also expected by FDA. FDA inspectors were no longer satisfied with being presented the odd risk assessment, rather than a company-wide approach to quality risk management.

Other regulatory agencies
Though the given examples resulted from US FDA inspections, there is no reason to believe other agencies do not or will not apply a similarly tough approach. In these and similar cases, the issue was that companies either failed to maintain their quality management system in a state of compliance with the applicable regulations and guidances, or that their attitude to resolving identified issues was neither holistic, nor investigative enough. This is a clear sign that there just is no room and time for complacency and failure to keep up with the developments in regulatory expectations. Just because inspectors sometimes provide industry with some leeway during inspections does not give them any right to flaunt the regulations and compromise compliance. Compliance really is an attitude, one that has to be understood, embraced, and implemented by everyone in the organization, including top management.

References
1. FDA, Compliance Program Guidance Manual, 7356.002F, http://www.fda.gov/ICECI/ComplianceManuals/ComplianceProgramManual/ucm2005382.htm, accessed July 15, 2013.
2. EMA, Compilation of Community Procedures on Inspections and Exchange of Information, EMA/INS/GMP/459921/2010 Rev 13.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here